BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 8671503)

  • 1. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone.
    Herman A; Raziel A; Strassburger D; Soffer Y; Bukovsky I; Ron-El R
    Hum Reprod; 1996 Jul; 11(7):1552-7. PubMed ID: 8671503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
    Valbuena D; Pellicer A; Guanes PP; Remohí J; Simón C
    Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteal phase support and severe ovarian hyperstimulation syndrome.
    McClure N; Leya J; Radwanska E; Rawlins R; Haning RV
    Hum Reprod; 1992 Jul; 7(6):758-64. PubMed ID: 1500471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
    Mochtar MH; Hogerzeil HV; Mol BW
    Hum Reprod; 1996 Aug; 11(8):1602-5. PubMed ID: 8921100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
    Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
    J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
    Peñarrubia J; Balasch J; Fábregues F; Creus M; Casamitjana R; Ballescá JL; Puerto B; Vanrell JA
    Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated GnRH agonist doses for luteal support: a proof of concept.
    Wiser A; Klement AH; Shavit T; Berkovitz A; Koren RR; Gonen O; Amichay K; Shulman A
    Reprod Biomed Online; 2019 Nov; 39(5):770-776. PubMed ID: 31628035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization.
    Kaye L; Griffin D; Thorne J; Neuber E; Nulsen J; Benadiva C; Engmann L
    Fertil Steril; 2019 Sep; 112(3):534-544. PubMed ID: 31227286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2011 Oct; (10):CD009154. PubMed ID: 21975790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
    Kol S; Humaidan P; Itskovitz-Eldor J
    Hum Reprod; 2011 Oct; 26(10):2874-7. PubMed ID: 21784738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the luteal phase after ovarian stimulation: reviewing new options.
    Yding Andersen C; Vilbour Andersen K
    Reprod Biomed Online; 2014 May; 28(5):552-9. PubMed ID: 24656557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.